WallStreetZenWallStreetZen

NYSE: JNJ
Johnson & Johnson Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnershipStatistics
Johnson & Johnson earnings were $21.0B for the trailing 12 months ending Jun 28, 2026, with -7.2% growth year over year. The latest JNJ earnings report on Jun 28, 2026 announced Q2 2026 earnings of $5.5B, up 5.7% from last quarter. For the last reported fiscal year 2025 ending Dec 28, 2025, JNJ reported annual earnings of $26.8B, with 90.6% growth.

JNJ past earnings growth

How has JNJ's earnings growth performed historically?

Company
-7.23%
Industry
29.56%
Market
95.3%
JNJ's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
JNJ's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
JNJ's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

JNJ earnings history

Current Revenue
$97.9B
Current Earnings
$21.0B
Current Profit Margin
21.5%
JNJ's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

JNJ Return on Equity

Current Company
25.7%
Current Industry
25.9%
Current Market
30.9%
JNJ's Return on Equity (25.7%)... subscribe to Premium to read more.
High Return on Equity Performance

JNJ Return on Assets

Current Company
10.6%
Current Industry
11.1%
JNJ is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when JNJ announces earnings.

JNJ Return on Capital Employed

Current Company
17.93%
Current Industry
19.6%
JNJ has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

JNJ vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
JNJ$33.96B$21.04B+5.31%$8.73
ABBV$19.21B$6.31B-0.66%$3.55
MRK$14.41B$3.17B-10.41%$1.27
NVS$28.35B$12.76B+10.85%$6.66
AZN$20.67B$10.45B+18.54%$6.74
View Top General Drug Manufacturer Stocks

Johnson & Johnson Earnings Reports & History FAQ

What were Johnson & Johnson's earnings last quarter?

On JNJ's earnings call on Jul 15, 2026, Johnson & Johnson (NYSE: JNJ) reported Q2 2026 earnings per share (EPS) of $2.30, up 0% year over year. Total JNJ earnings for the quarter were $5.53 billion. In the same quarter last year, Johnson & Johnson's earnings per share (EPS) was $2.30.

If you're new to stock investing, here's how to buy Johnson & Johnson stock.

Is Johnson & Johnson profitable or losing money?

As of the last Johnson & Johnson earnings report, Johnson & Johnson is currently profitable. Johnson & Johnson's net profit (also called net income) for the twelve months ending Jun 28, 2026 was $21.04 billion, a 7.17% decrease year over year.

What was JNJ's earnings growth in the past year?

As of Johnson & Johnson's earnings date in Jul 15, 2026, Johnson & Johnson's earnings has grown -7.23% year over year. This is 36.79 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 29.56%. JNJ earnings in the past year totalled $21.04 billion.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.